1921
Volume 93, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

The synergy between infection and human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome is well established but not so in Buruli ulcer (BU). We screened confirmed BU cases for HIV infection and followed seven BU/HIV-coinfected patients. Management of BU/HIV was based on the World Health Organization guidelines and patient condition. The HIV positivity among BU patients (8.2%; 11/134) was higher compared with that of general patients attending the facility (4.8%; 718/14,863; = 0.07) and that of pregnant women alone (2.5%; 279/11,125; = 0.001). All seven BU/HIV-coinfected cases enrolled in the study presented with very large (category III) lesions with four having multiple lesions compared with 54.5% of category III lesions among HIV-negative BU patients. During the recommended BU treatment with streptomycin and rifampicin (SR) all patients developed immune infiltrates including CD4 T cells in their lesions. However, one patient who received antiretroviral therapy (ART) 1 week after beginning SR treatment developed four additional lesions during antibiotic treatment, while two out of the four who did not receive ART died. Further evidence is required to ascertain the most appropriate time to commence ART in relation to SR treatment to minimize paradoxical reactions.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.14-0571
2015-08-05
2017-09-23
Loading full text...

Full text loading...

/deliver/fulltext/14761645/93/2/216.html?itemId=/content/journals/10.4269/ajtmh.14-0571&mimeType=html&fmt=ahah

References

  1. Sizaire V, Nackers F, Comte E, Portaels F, , 2006. Mycobacterium ulcerans infection: control, diagnosis and treatment. Lancet Infect Dis 6: 288296.[Crossref]
  2. Van der Werf TS, Van der Graaf WTA, Tappero JW, Asiedu K, , 1999. Mycobacterium ulcerans infection. Lancet 353: 10131101.[Crossref]
  3. Agbenorku P, , 2014. Buruli ulcer disability in Ghana: the problems and solutions. BJMMR 4: 13551365.[Crossref]
  4. Pszolla N, Sarkar RM, Strecker W, Kern P, Kinzl L, , 2003. Buruli ulcer: a systemic disease. Clin Infect Dis 37: 7882.[Crossref]
  5. Converse PJ, Nuermberger EL, Almeida DV, Grosset JH, , 2011. Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife? Future Microbiol 6: 11851198.[Crossref]
  6. O'Brien DP, Comte E, Serafi M, Ehounou G, Antierens A, , 2013. The urgent need for clinical, diagnostic, and operational research for management of Buruli ulcer in Africa. Lancet Infect Dis 14: 435440.[Crossref]
  7. Etuaful S, Carbonnelle B, Lucas S, Horsefield C, Philips R, , 2005. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 49: 31823186.[Crossref]
  8. Chauty A, Ardant MF, Adeye A, Euverte H, Guedenon A, , 2007. Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 51: 40294035.[Crossref]
  9. Sarfo FS, Philips R, Asiedu K, Ampadu E, Bobi N, , 2010. Clinical efficacy of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 54: 36783685.[Crossref]
  10. Adusumilli S, Mve-Obiang A, Sparer T, Meyers W, Hayman J, , 2005. Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbiol 7: 12951304.[Crossref]
  11. Peduzzi E, Groeper C, Schütte D, Zajac P, Rondini S, , 2007. Local activation of the innate immune system in Buruli ulcer lesions. J Invest Dermatol 12: 638645.[Crossref]
  12. Schütte D, Um-Boock A, Mensah-Quainoo E, Itin P, Schmid P, , 2007. Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin. PLoS Negl Trop Dis 1: e2.[Crossref]
  13. Ruf M-T, Chauty A, Adeye A, Ardant MF, Koussemou H, , 2011. Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence of immune protection? PLoS Negl Trop Dis 5: e1252.[Crossref]
  14. Wanda F, Nkemenang P, Ehounou G, Tchaton M, Comte E, , 2014. Clinical features and management of a severe paradoxical reaction associated with combined treatment of Buruli ulcer and HIV co-infection. BMC Infect Dis 14: 423.[Crossref]
  15. Yeboah-Manu D, Kpeli GS, Ruf M-T, Asan-Ampah K, Quenin-Fosu K, , 2013. Secondary bacterial infections of Buruli ulcer lesions before and after chemotherapy with streptomycin and rifampicin. PLoS Negl Trop Dis 7: e2191.[Crossref]
  16. Christinet V, Comte E, Ciaffi L, Odermatt P, Serafini M, Antierens A, Rossel L, Nomo AB, Nkemenang P, Tsoungui A, Delhumeau C, Calmy A, , 2014. Impact of HIV on the severity of Buruli ulcer disease: results of a retrospective study in Cameroon. Open Forum Infect Dis 1: ofu021.[Crossref]
  17. Toll A, Gallardo F, Ferran M, Gilaberte M, Iglesias M, , 2005. Aggressive multifocal Buruli ulcer with associated osteomyelitis in an HIV-positive patient. Clin Exp Dermatol 30: 649651.[Crossref]
  18. Komenan K, Elidjé EJ, Ildevert GP, Yao KI, Kanga K, Kouame KA, Abdoulaye S, Hamdam KS, Yao YP, Jean-Marie K, , 2013. Multifocal Buruli ulcer associated with secondary infection in HIV positive patient. Case Rep Med 2013: 348628.
  19. Peloquin CA, Nitta AT, Burman WJ, Brudney KF, Miranda-Massari JR, McGuinness MF, Berning SE, Gerana GT, , 1996. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 30: 919925.[Crossref]
  20. Taylor J, Smith PJ, , 1998. Does AIDS impair the absorption of antituberculosis agents? Int J Tuberc Lung Dis 2: 670675.
  21. Girma M, Teshome W, Petros B, Endeshaw T, , 2014. Cryptosporidiosis and isosporiasis among. HIV-positive individuals in south Ethiopia: a cross sectional study. BMC Infect Dis 14: 100.[Crossref]
  22. Shastri S, Naik B, Anita Shet A, Bharat Rewari B, De Costa A, , 2013. TB treatment outcomes among TB-HIV co-infections in Karnataka, India: how do these compare with non-HIV tuberculosis outcomes in the province? BMC Public Health 13: 838.[Crossref]
  23. Havlir DV, Getahun H, Sanne I, Nunn P, , 2008. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 300: 423430.[Crossref]
  24. Jones BE, Young SM, Antoniskis D, Davidson PT, Kramer F, Barnes PF, , 1993. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 148: 12921297.[Crossref]
  25. Torrado E, Fraga AG, Castro AG, Stragier P, Mayers WM, , 2006. Evidence for intramacrophage growth phase of Mycobacterium ulcerans . Infect Immun 75: 977987.[Crossref]
  26. Oliveira MS, Fraga AG, Torrado E, Castro AG, Pereira JP, , 2005. Infection with Mycobacterium ulcerans induces persistent inflammatory response in mice. Infect Immun 73: 62996310.[Crossref]
  27. Yeboah-Manu D, Peduzzi E, Mensah-Quainoo E, Asante-Poku A, Ofori-Adjei D, , 2006. Systemic suppression of interferon-γ responses in Buruli ulcer patients resolves after surgical excision of the lesions caused by the extracellular pathogen Mycobacterium ulcerans . J Leukoc Biol 79: 11501156.[Crossref]
  28. Palella FJ, Jr Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Glen A, Satten GA, Aschman DA, Holmberg SD, , 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853860.[Crossref]
  29. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, Knysz B, Dietrich M, Philips AN, Lundgren JD, , 2003. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362: 2229.[Crossref]
  30. Meintjes G, Boulle A, , 2012. Immune reconstitution inflammatory syndrome in a large multicenter cohort study: case definition and comparability. Expert Rev Anti Infect Ther 10: 737741.[Crossref]
  31. Achenbach CJ, Harrington RD, Dhanireddy S, Crane HM, Casper C, Kitahata MM, , 2012. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combined antiretroviral therapy after AIDS-defining opportunistic infections. Clin Infect Dis 54: 424433.[Crossref]
  32. Hercberg S, Chauliac M, Galan P, Devanlay M, Zohoun I, Agboton Y, Soustre Y, Auvert B, Masse-Raimbault AM, Dupin H, , 1988. Prevalence of iron deficiency and iron-deficiency anaemia in Benin. Public Health 102: 7383.[Crossref]
  33. Stienstra Y, van der Werf TS, Oosterom E, Nolte IM, van der Graaf WT, Etuaful S, Raghunathan PL, Whitney EA, Ampadu EO, Asamoah K, Klutse EY, te Meerman GJ, Tappero JW, Ashford DA, van der Steege G, , 2006. Susceptibility to Buruli ulcer is associated with the SLC11A1 (NRAMP1) D543N polymorphism. Genes Immun 7: 185189.[Crossref]
  34. Van Zandt KE, Sow FB, Florence WC, Zwilling BS, Satoskar AR, Schlesinger LS, Lafuse WP, , 2008. The iron export protein ferroportin 1 is differentially expressed in mouse macrophage populations and is present in the mycobacterial-containing phagosome. J Leukoc Biol 84: 689700.[Crossref]
  35. Lundgren JD, Mocroft A, , 2003. Anemia and survival in human immunodeficiency virus. Clin Infect Dis 37: S297S303.[Crossref]
  36. Ferede G, Wondimeneh Y, , 2013. Prevalence and related factors of anemia in HAART-naive HIV positive patients at Gondor University Hospital, northwest Ethiopia. BMC Haematol 13: 205.
  37. Mensah-Quainoo E, Yeboah-Manu D, Asebi C, Patafuor F, Ofori-Adjei D, Junghanss T, Pluschke G, , 2008. Diagnosis of Mycobacterium ulcerans infection (Buruli ulcer) at a treatment centre in Ghana: a retrospective analysis of laboratory results of clinically diagnosed cases. Trop Med Int Health 13: 191198.[Crossref]
  38. O'Connell RJ, Merritt TM, Malia JA, VanCott TC, Dolan MJ, , 2003. Performance of the OraQuick rapid antibody test for diagnosis of human immunodeficiency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapy. J Clin Microbiol 41: 21532155.[Crossref]
  39. Yeboah-Manu D, Asante-Poku A, Asan-Ampah K, Ampadu ED, Pluschke G, , 2011. Combining PCR with microscopy to reduce costs of laboratory diagnosis of Buruli ulcer. Am J Trop Med Hyg 85: 900904.[Crossref]
  40. Yeboah-Manu D, Konadu E, Asan-Ampah K, Asante-Poku A, Nakobu Z, Pluschke G, , 2011. Isolation of Mycobacterium ulcerans from swab and fine-needle-aspiration specimens. J Clin Microbiol 49: 19971999.[Crossref]
  41. Myers BA, , 2011. Wound Management: Principles and Practices, 3rd edition. Upper Saddle River, NJ: Prentice Hall.
  42. WHO Portaels F, Johnson P, Meyers WM, , 2001. Buruli Ulcer: Diagnosis of Mycobacterium ulcerans Disease. , eds. Geneva, Switzerland: World Health Organization.
  43. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, Tuah W, Awuah-Boateng NY, Ampadu EO, Slegmund V, Schouten JP, Adjei O, Bretzel G, van der Werf TS, , 2010. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 375: 664672.[Crossref]
  44. Johnson RC, Nackers F, Glynn JR, de Biurrun Bakedano E, Zinsou C, Aguiar J, Tonglet R, Portaels F, , 2008. Association of HIV infection and Mycobacterium ulcerans disease in Benin. AIDS 22: 901903.[Crossref]
  45. Opie J, , 2012. Haematological complications of HIV infection. S Afr Med J 102: 465468.[Crossref]
  46. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y, Marcy O, Chan S, Prak N, Kim C, Lak KK, Hak C, Dim B, Sin CI, Sun S, Guillard B, Sar B, Vong S, Fernandez M, Fox L, Deifraissy JF, Goldfeld AE, , 2011. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 365: 14711481.[Crossref]
  47. Boulware DR, Meya DB, Muzoora C, Rolfes MA, Hullsiek KH, Musubire A, Taseera K, Nabeta HW, Schutz C, Williams DA, Rajasingham R, Rhein J, Thienemann F, Lo MW, Nielsen K, Bergemann TL, Kambugu A, Manabe YC, Janoff EN, Bohjanen PR, Meintjes G, COAT Trial Team; , 2014. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med 370: 24872498.[Crossref]
  48. Ribera E, Pou L, Lopez RM, Crispo M, Falvo V, , 2001. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr 28: 450453.[Crossref]
  49. Kadima JN, Mukanyangezi MF, Uwizeye CB, , 2014. Effectiveness and safety of concurrent use of first line antiretroviral and antituberculous drugs in Rwanda. J Trop Med 2014: 9.[Crossref]
  50. Pillay P, Ford N, Shubber Z, Ferrand RA, , 2013. Outcomes of efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis. PLoS One 8: E68995.[Crossref]
  51. O'Brien DPO, Ford N, Vitoria M, Christinet V, Comte E, Calmy A, Stienstra Y, Eholie S, Asiedu K, , 2014. Management of HIV-BU co-infection. Trop Med Int Health 19: 10401047.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.14-0571
Loading
/content/journals/10.4269/ajtmh.14-0571
Loading

Data & Media loading...

  • Received : 12 Sep 2014
  • Accepted : 13 Mar 2015

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error